Results for Fourth Quarter and Preliminary Results for Medistim for 2018

Record sales for the quarter with a 19.1 % growth at MNOK 97.0 (MNOK 82.2). Sales for 2018 ended at MNOK 325.9 (MNOK 301.5), a growth of 8.1 %.

Currency neutral sales of own products increased with 25.5 % for the quarter. For 2018, currency neutral growth in sales of own products was 10.0%. EBIT for the quarter ended at MNOK 27.8 (MNOK 16.4), a 69.6 %growth. For 2018 EBIT ended at MNOK 74.0 (MNOK 65.5) a 13.0 % growth.
Read the full financial report and presentation below.

Q4 2018 Presentation

Q4 and preliminary year-end financials 2018